Tectonic Therapeutic, Inc. (TECX) Stock Score, Valuation & Financial Research

Tectonic Therapeutic, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TECX

Tectonic Therapeutic, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 23.26. These figures are a research snapshot, not a buy or sell recommendation.

What Tectonic Therapeutic, Inc. does

Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tectonic Therapeutic is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and potential future collaborations to fund the research and development of its proprietary GEODe platform and GPCR-targeted biologic candidates.

Products and services

  • The company is developing a pipeline of therapeutic proteins and antibodies targeting G-protein coupled receptors (GPCRs), including lead candidates TX45 and TX2100.

Customer types

Healthcare providers and patients with unmet medical needs.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, laboratory services, and the manufacturing of clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Proprietary GEODe discovery platform for GPCR-targeted biologics Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party clinical trial and manufacturing partners Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TECX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 23.26
Market capitalization:
438.92M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -85.79M
Free cash flow:
USD -60.29M
Cash:
USD 227.07M
Total debt:
USD 4.4M
EPS:
USD -4.57

What stands out

  • Free cash flow is USD -60.29M, negative for the stored period.
  • The balance sheet shows USD 227.07M of cash versus USD 4.4M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 222.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TECX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TECX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TECX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TECX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TECX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TECX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.